Skip to main content

Table 2 Multivariate analysis of the impact of demographic, laboratory, and molecular parameters on overall survival in the entire study group

From: Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

  P-value HR 95% CI
Lower Upper
Age 0.019 1.032 1.005 1.060
Sex 0.688 0.881 0.476 1.631
FLT3 mutation 0.222 1.521 0.775 2.985
NPM1 mutation 0.476 1.306 0.627 2.720
DNMT3A mutation 0.026 2.552 1.120 5.816
IDH 1 mutation 0.002 0.223 0.085 0.588
IDH 2 mutation 0.134 0.407 0.125 1.320
Poor risk cytogenetics* 0.018 4.584 1.297 16.199
CN-AML 0.358 1.596 0.589 4.328
BM blast percentage 0.487 0.995 0.981 1.009
PB blast percentage 0.692 1.002 0.992 1.012
Hemoglobin 0.864 0.984 0.816 1.186
White blood count 0.640 1.002 0.995 1.008
  1. Include 17 cases with IDH2R140 and 2 with IDH2R172[25].
  2. *Poor-risk vs intermediate and better risk categories per National Comprehensive Cancer Network guidelines (version 2.2013) [26].
  3. Abbreviations: HR hazards ratio, CI confidence interval, BM bone marrow, PB peripheral blood, CN-AML cytogenetically normal (diploid) acute myeloid leukemia.
  4. Bold font indicates parameters with significant impact on overall survival.